Graphical Abstract
![](https://wqketang.oss-cn-beijing.aliyuncs.com/zip-unzip/zip-468520c7-6c3d-4120-9ee5-0757d834a6ef/iliver-3-2-100095/files/iliver-3-2-100095-FE1.jpg?Expires=1725756257&OSSAccessKeyId=STS.NSssK71aLjDMY9SbRgGRGskMT&Signature=2HYE7IYNc%2BYXE1%2BVlHNsIQ6Qiic%3D&security-token=CAISywJ1q6Ft5B2yfSjIr5DGOPGD3L5t3YamWx%2FihlIyS91rnK7mtjz2IHtKenhsBOsbtfk1mG5W5%2FgZlqJ9SptIAEfJa9d99Myjb%2F9FltCT1fau5Jko1beHewHKeTOZsebWZ%2BLmNqC%2FHt6md1HDkAJq3LL%2Bbk%2FMdle5MJqP%2B%2FUFB5ZtKWveVzddA8pMLQZPsdITMWCrVcygKRn3mGHdfiEK00he8TouufTinpHMskGA1Aell7Mvyt6vcsT%2BXa5FJ4xiVtq55utye5fa3TRYgxowr%2Fwo0v0YpGya5YzHXwcPskvdKZbo78UqLQlla6w%2BGqFJqvPxr%2Fp8t%2Fx5fWJKAezhVgs8cVM8JOjIqKOscIsixo262SmqFV55c8Fdm%2BgUooJVgIMhTnduUfAPJAGOxzJitP%2BUVGGphr60TEnBL4rB5MUctfzRpwT64j3UTzDnGoABhFRSspTLrn9GrEN9pQYzC6eepGdfWDQh3fr5hA1VnwVUJMCz%2BNQEDWKceF%2FnEjWVMtfbvqYxuyhSCmIMMyh5bEREEKEiD%2BFVv4ZfsqnV7hQy5w6HhIkN8kZzP6L0zPvPgkBLOtdMDeDxhf8dVPrCSG4etXHjxcwUaRVb3ZR7Yu8gAA%3D%3D)
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Currently, research on biopsy-proven acute drug-induced liver injury (DILI) remains limited. This study aimed to identify clinical characteristics and risk factors for significant hepatic inflammation in patients with acute DILI.
An ambispective cohort study was conducted on biopsy-proven acute DILI patients admitted to our hospital from 2012 to 2018. Using the Scheuer scoring system, patients were categorized into G0-2 or G3-4 groups and followed up for 12 months after first admission. Clinical characteristics and outcomes were retrieved from medical records.
The median age of the 157 enrolled patients (65.6% female) was 40.4 (interquartile range (IQR), 31.9–49.1) years. The median latency and length of hospitalization were 30.0 (IQR, 5.0–60.0) and 18.0 (IQR, 12.0–26.0) days. The proportions of patients in the G0-2 and G3-4 groups were 54.8% and 45.2%, respectively. Logistic regression analysis revealed that females (odds ratio (OR): 2.623, 95% confidence interval (CI): 1.169–5.887, p = 0.019), higher body mass index (OR: 1.168, 95% CI: 1.029–1.325, p = 0.016), higher total bilirubin (OR: 1.004, 95% CI: 1.000–1.007, p = 0.047), and lower prothrombin activity (OR: 0.976, 95% CI: 0,957–0.995, p = 0.013) were associated with significant hepatic inflammation. The predominance of the hepatocellular injury pattern (60.5%) at admission transformed into a predominance of the cholestatic pattern (60.5%) at discharge. During follow-up, 23 patients (14.6%) developed chronic DILI, with nine patients (5.7%) progressing to cirrhosis. Moreover, 15 female patients (9.6%) developed autoimmunity (3cases in the G0-2 group vs 12 cases in the G3-4 group, p < 0.05).
Acute DILI patients with high-risk factors were more likely to develop significant hepatic inflammation, and females with significant inflammation were at a higher risk of developing autoimmunity during follow-up.
Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019;5(1):58. https://doi.org/10.1038/s41572-019-0105-0.
Gerussi A, Natalini A, Antonangeli F, et al. Immune-mediated drug-induced liver injury: immunogenetics and experimental models. Int J Mol Sci 2021;22(9):4557. https://doi.org/10.3390/ijms22094557.
Patel S, Chaturvedi A, Dubey N, et al. Ascorbic acid ameliorates isoniazid-rifampicin-induced hepatocellular damage in rats. iLIVER 2022;1(1):72–7. https://doi.org/10.1016/j.iliver.2022.03.001.
Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 2019;156(8):2230–41.e11. https://doi.org/10.1053/j.gastro.2019.02.002.
Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 2016;65(3):532–42. https://doi.org/10.1016/j.jhep.2016.05.003.
Björnsson ES. Clinical management of patients with drug-induced liver injury (DILI). United European Gastroenterol J 2021;9(7):781–6. https://doi.org/10.1002/ueg2.12113.
Re VL 3rd, Haynes K, Forde KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of hy's law and a new prognostic model. Clin Gastroenterol Hepatol 2015;13(13):2360–8. https://doi.org/10.1016/j.cgh.2015.06.020.
Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int 2022;42(9):1999–2014. https://doi.org/10.1111/liv.15262.
Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2021;116(5):878–98. https://doi.org/10.14309/ajg.0000000000001259.
Zeng G, Eslick GD, Weltman M. Systematic review and meta-analysis: comparing hepatocellular and cholestatic patterns of drug-induced liver injury. iLIVER 2023;2(2):122–9. https://doi.org/10.1016/j.iliver.2023.05.002.
Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59(2):661–70. https://doi.org/10.1002/hep.26709.
Cai SY, Boyer JL. The role of bile acids in cholestatic liver injury. Ann Transl Med 2021;9(8):737. https://doi.org/10.21037/atm-20-5110.
Andrade RJ, Aithal GP, Björnsson ES, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019;70(6):1222–61. https://doi.org/10.1016/j.jhep.2019.02.014.
Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 2015;63(2):503–14. https://doi.org/10.1016/j.jhep.2015.04.016.
Allison R, Guraka A, Shawa IT, et al. Drug induced liver injury—a 2023 update. J Toxicol Environ Health B Crit Rev 2023;26(8):442–67. https://doi.org/10.1080/10937404.2023.2261848.
Wang Q, Huang A, Wang JB, et al. Chronic drug-induced liver injury: updates and future challenges. Front Pharmacol 2021;12:627133. https://doi.org/10.3389/fphar.2021.627133.
Suzuki A, Barnhart H, Gu J, et al. Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int 2017;37(11):1723–30. https://doi.org/10.1111/liv.13380.
Rathi C, Pipaliya N, Patel R, et al. Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol 2017;16(3):442–50. https://doi.org/10.5604/16652681.1235488.
Song FJ, Liu HL, Sun Y, et al. Prednisolone therapy accelerates recovery of severe drug-induced liver injury: a prospective, randomized controlled study. iLIVER 2023;2(3):156–62. https://doi.org/10.1016/j.iliver.2023.06.001.
Xiong YT, Wang JF, Niu XX, et al. Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. Front Pharmacol 2023;14:1071709. https://doi.org/10.3389/fphar.2023.1071709.
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63(4):971–1004.10.1016/j.jhep.2015.06.030
Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009;50(3):511–7. https://doi.org/10.1016/j.jhep.2008.10.021.
Kong X, Guo D, Liu S, et al. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: a matched case-control study. Br J Clin Pharmacol 2021;87(11):4304–12. https://doi.org/10.1111/bcp.14847.
Floreani A, Bizzaro D, Shalaby S, et al. Sex disparity and drug-induced liver injury. Dig Liver Dis 2023;55(1):21–8. https://doi.org/10.1016/j.dld.2022.06.025.
Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148(7):1340–52.e7. https://doi.org/10.1053/j.gastro.2015.03.006.
Bessone F, Hernandez N, Mendizabal M, et al. When the creation of a consortium provides useful answers: experience of the Latin American DILI network (LATINDILIN). Clin Liver Dis (Hoboken) 2019;13(2):51–7. https://doi.org/10.1002/cld.778.
Isabel Lucena M, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49(6):2001–9. https://doi.org/10.1002/hep.22895.
Cho J, Kim L, Li Z, et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mi suggested roles for Tregs, estrogen, and IL-6. PLoS One 2013;8(4):e61186. https://doi.org/10.1371/journal.pone.0061186.
Chalasani N, Fontana RJ, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians. Am J Gastroenterol 2017;112(9):1382–8. https://doi.org/10.1038/ajg.2017.215.
Chomchai S, Chomchai C. Being overweight or obese as a risk factor for acute liver injury secondary to acute acetaminophen overdose. Pharmacoepidemiol Drug Saf 2018;27(1):19–24. https://doi.org/10.1002/pds.4339.
Fromenty B. Drug-induced liver injury in obesity. J Hepatol 2013;58(4):824–6. https://doi.org/10.1016/j.jhep.2012.12.018.
Ma Z, Li M, Wang Y, et al. Association of BMI with mortality in drug-induced liver injury. Eur J Gastroenterol Hepatol 2024;36(2):220–8. https://doi.org/10.1097/MEG.0000000000002689.
Lu RJ, Zhang Y, Tang FL, et al. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med 2016;12(4):2606–16. https://doi.org/10.3892/etm.2016.3627.
Raschi E, De Ponti F. Drug-induced liver injury: towards early prediction and risk stratification. World J Hepatol 2017;9(1):30–7. https://doi.org/10.4254/wjh.v9.i1.30.
Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014;147(1):96–108.e4. https://doi.org/10.1053/j.gastro.2014.03.045.
Ashby K, Zhuang W, González-Jimenez A, et al. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol 2021;75(2):333–41. https://doi.org/10.1016/j.jhep.2021.03.021.
Zhu W, Wang L, Zhao X, et al. Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury. Hepatol Res 2020;50(2):224–32. https://doi.org/10.1111/hepr.13435.
Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology 2022;75(6):1373–85. https://doi.org/10.1002/hep.32283.
Sutti S, Tacke F. Liver inflammation and regeneration in drug-induced liver injury: sex matters!. Clin Sci (Lond) 2018;132(5):609–13. https://doi.org/10.1042/CS20171313.
Tan CK, Ho D, Wang LM, et al. Drug-induced autoimmune hepatitis: a minireview. World J Gastroenterol 2022;28(24):2654–66. https://doi.org/10.3748/wjg.v28.i24.2654.
He T, Ren L, Gong M, et al. The progression of chronicity and autoimmune hepatitis in recurrent drug-induced liver injury. Clin Res Hepatol Gastroenterol 2022;46(10):102009. https://doi.org/10.1016/j.clinre.2022.102009.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).